DUBLIN–(BUSINESS WIRE)–The «U.S. Cryogenic Biobanking Services Market – Industry Outlook & Forecast 2025-2030» report has been added to ResearchAndMarkets.com’s offering.
The U.S. Cryogenic Biobanking Services Market was valued at USD 5.89 billion in 2024, and is projected to reach USD 8.29 billion by 2030, rising at a CAGR of 5.86%.
MARKET TRENDS & DRIVERS
Expansion of Virtual Biobanking
The expansion of virtual biobanking is a game-changer in the U.S. cryogenic biobanking services market. By bridging the gap between physical sample storage and digital data accessibility, it unlocks new potential for collaboration, research efficiency, and personalized medicine. With continued advancements and supportive regulatory frameworks, virtual biobanking will play a pivotal role in shaping the future of biomedical science.
Growing Conservation of Cord Blood Stem Cells of Newborns
The growing conservation of cord blood stem cells represents a transformative trend in the U.S. cryogenic biobanking services market. With its potential to revolutionize treatments for a wide range of diseases and its role in advancing regenerative medicine, cord blood banking is driving innovation and creating new opportunities for biobanking providers. By embracing this trend and overcoming associated challenges, the market is set to make significant contributions to healthcare and scientific advancements in the years to come.
Advancements in Cryopreservation Technology
Advancements in cryopreservation technology are revolutionizing the U.S. cryogenic biobanking services market, offering unprecedented opportunities for biomedical research, personalized medicine, and regenerative therapies. By enhancing the quality and longevity of biological samples, these innovations are driving progress in healthcare and opening new avenues for discovery. One of the most significant advancements in cryopreservation technology is the development of vitrification. This method involves ultra-rapid cooling, which prevents the formation of ice crystals that can damage cells, tissues, and other biological materials.
Emergence of Personalized Biobanking
With the rise of personalized medicine, the demand for tailored therapies and treatments is higher than ever, and biobanks are uniquely positioned to support this transformation. By providing valuable insights into individual health profiles, personalized biobanks are unlocking new opportunities in drug development, disease prevention, and precision medicine. Moreover, with the rapid progress in genomic technologies such as next-generation sequencing (NGS), personalized biobanks have become essential in the study of genomics and precision medicine. The ability to sequence an individual’s genome and analyze genetic predispositions, disease risks, and drug responses is unlocking unprecedented opportunities in targeted therapies.
Rising Prevalence of Chronic Diseases
The rising prevalence of chronic diseases in the U.S. has significantly boosted the demand for cryogenic biobanking services. By providing essential resources for research, diagnostics, and therapeutics, biobanking serves as a cornerstone in addressing the chronic disease burden. As the healthcare landscape evolves, cryogenic biobanking is poised to remain a vital tool in advancing medical science, improving patient outcomes, and transforming the way chronic diseases are understood and treated.
Surge in Clinical Trials for New Drugs and Therapies
The surge in clinical trials for new drugs and therapies is undeniably a driving force in the U.S. cryogenic biobanking services market. As the demand for efficient sample storage and management continues to grow, cryogenic biobanking will remain at the forefront of medical research and innovation. By supporting the development of life-saving treatments and therapies, the biobanking market is not only fueling market growth but also contributing to the advancement of global healthcare.
Expansion of Genomics and Proteomics Research
The expansion of genomics and proteomics research is a driving force behind the growth of the United States cryogenic biobanking services market. By providing essential storage solutions for biological specimens, cryogenic biobanks are enabling groundbreaking discoveries in precision medicine, disease diagnostics, and therapeutic development. As these fields continue to evolve, the role of cryogenic biobanking will remain pivotal in advancing the frontiers of medical and biological research, ultimately transforming patient care and health outcomes.
Favorable Government and Private Funding
Favorable government and private funding have undeniably been key drivers of the U.S. cryogenic biobanking services market. By supporting infrastructure development, technological innovation, and collaborative research, these funding efforts have positioned the U.S. as a global leader in biobanking. Examples like the NIH’s All of Us program and private sector partnerships highlight the profound impact of financial backing, paving the way for innovative breakthroughs and improved healthcare outcomes.
COMPETITIVE LANDSCAPE
The U.S. cryogenic biobanking services market is a dynamic and competitive sector, fueled by the rising demand for long-term preservation of biological specimens for research, clinical, and commercial purposes. The competitive landscape is characterized by the presence of established market leaders, emerging players, and niche service providers. Companies in this market compete based on factors such as technological innovation, service diversity, quality assurance, compliance with regulatory standards, and strategic partnerships. Furthermore, the United States cryogenic biobanking services market is dominated by several established players, including specialized service providers, contract biobanking companies, and academic and healthcare institutions offering cryogenic storage solutions.
Furthermore, to maintain their positions and attract new clients, companies in the U.S. cryogenic biobanking services market employ a variety of competitive strategies. For instance, companies are expanding their service portfolios to include additional offerings such as disaster recovery solutions, regulatory consulting, and data integration with laboratory information management systems (LIMS). Also, many firms prioritize flexibility in service offerings, such as custom biobanking solutions tailored to specific client requirements, to differentiate themselves in the market.
Company Profiles
- Azenta Life Sciences
- BioDock (Future Health Group)
- BioKryo
- BioRepository Resources (Tobin Scientific)
- Biostorage
- BocaBio
- Brigham and Women’s Hospital Division of Preventive Medicine
- Cell Culture Company
- Cleveland Clinic
- Coriell Institute
- Cryo Bio System
- Cryoport Systems
- CRYOTHERM
- Cureline
- Custom BioGenic Systems
- Duke University and Duke University Health System
- Greiner Bio-One International GmbH
- Kaiser Permanente
- Mayo Clinic
- Northwestern University
- Personalized Stem Cells
- Precision Stability Storage
- REPROCELL
- Rhode Island Biobank (Brown University)
- RUSH University
- Sampled
- SCISAFE
- SPT Labtech
- Stanford University
- Tecan Trading AG
- The Johns Hopkins University
- The University of Arizona
- The University of Chicago Medical Center
- The University of Iowa
- The University of Pennsylvania
- The University of Texas MD Anderson Cancer Center
- Thermo Fisher Scientific
- Thermogenesis Holdings
- University of South Alabama
- Washington University
- WiCell
-
Yale School of Medicine
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 246 |
| Forecast Period | 2024 – 2030 |
| Estimated Market Value (USD) in 2024 | $5.89 Billion |
| Forecasted Market Value (USD) by 2030 | $8.29 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | United States |
Key Topics Covered:
Market Opportunities & Trends
- Growing Conservation of Cord Blood Stem Cells of Newborns
- Expansion of Virtual Biobanking
- Advances in Cryopreservation Technology
- Emergence of Personalized Biobanking
Market Growth Enablers
- Rising Prevalence of Chronic Diseases
- Surge in Clinical Trials for New Drugs and Therapies
- Expansion of Genomics and Proteomics Research
- Favorable Government and Private Funding
Market Restraints
- High Operational Costs
- Ethical Concerns and Consent Management
- Sample Quality and Viability Risks
For more information about this report visit https://www.researchandmarkets.com/r/40ol3a
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
